Keywords: Benlysta, Human Genome Sciences, GlaxoSmithKline, Lupus, SLE, Decision Resources
Benlysta heading in right direction, but uptake slower than originally expected, says BioTrends
Article | 07 August 2011
Rheumatologists are maintaining enthusiasm for Human Genome Sciences (Nasdaq: HGSI) and GlaxoSmithKline’s (LSE: GSK) Benlysta (belimumab), the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
